Generic ramipril not obvious to King
Executive Summary
King is hoping to delay entry of generics versions of its ACE inhibitor Altace (ramipril) with a motion for hearing and rehearing en banc following a Federal Circuit decision, which invalidated King's '722 patent on the basis of obviousness. The Federal Circuit overturned an earlier decision that had upheld the validity of King's patent, instead ruling in favor of appellant Lupin. Teva, Actavis, Sandoz, Roxane and Dr. Reddy's each have a tentative approval for generic ramipril. King is hoping to spark growth of its top product, which has accounted for 32 percent of the firm's sales over the last 12 months, by launching a new tablet formulation and by gaining approval of a ramipril/hydrochlorothiazide combination (1"The Pink Sheet" Aug. 13, 2007, p. 12)...
You may also be interested in...
Altace ANDAs On Hold Till June; Colbalt Gets Exclusivity, Not “Parking” Ticket
Lupin Pharmaceuticals and five other pharma companies will have to wait at least until June to market their versions of ramipril capsules (King's Altace), as FDA ruled that Cobalt Pharmaceuticals is entitled to the 180-day generic drug exclusivity it was granted in 2005
Altace Lifecycle Management And Remoxy NDA Filing Top King’s Agenda
King Pharmaceuticals's upcoming regulatory agenda includes near-term NDA filings for a co-formulation of the ACE inhibitor Altace and hydrochlorothiazide and the opioid Remoxy in conjunction with Pain Therapeutics
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.